One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the company ...

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

He never got a minor SARS-CoV2 infection either, according to rapid antigen/RT-PCR and nucleocapsid serology assays. The antibody titres were much greater than the control group vaccinees ...

President Donald Trump’s pick to lead the National Institutes of Health answered sharp questions in a confirmation hearing ...